CB2 Insights Licenses Electronic Data Capture Software to MyAccess Clinics for Use In the UK
September 19 2019 - 7:28AM
September 19, 2019
– CB2 Insights (CSE:CBII;
OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven
company focused on bringing real-world evidence driven from the
point-of-care to the medical cannabis community, today announced
that MyAccess Clinics (“MAC”) has selected CB2 Insights’ Electronic
Data Capture (EDC) software to manage patient data within its
growing number of medical clinics in the UK. MyAccess Clinics is a
wholly-owned subsidiary of leading global medical cannabis company,
Althea Group Holdings Ltd (ASX:AGH).
“The UK market continues to blossom at a rapid pace, and we are
proud that our research and data technology assets continue to be
sought to expedite growth in the market,” said Prad Sekar, Chief
Executive Officer, CB2 Insights. “MyAccess Clinics has an
exceptional and comprehensive vision for its development in the
UK’s medical cannabis market and we are excited to be a part of
that effort.”
CB2 Insights’ EDC software has been used throughout the US and
Canada and uses standard healthcare protocols. The system is
purpose-built for medical cannabis operations and takes into
account the complexity of managing data related to multiple
indications across a single patient base, comorbidity in certain
patient profiles, past traditional therapies and multiple
consumption methods and medicine within a single treatment
plan. The system works to simplify data input and management
while ensuring collection can ultimately be used to better
understand the efficacy of cannabinoid therapy. This
deployment will increase both the size and scope of the Company’s
data set.
Graham Woodward, MyAccess Clinics Clinical Director said “As a
company, we are proud to be one of the first to service the
emerging UK medical cannabis market. CB2 Insights’ software will
play an integral part in the administration of our clinics
and will increase our ability to manage data, thereby improving our
patient care.”
Earlier this year, CB2 Insights announced that it had been
selected as the exclusive research technology platform for UK-based
Drug Science and its medical cannabis pilot program.
About CB2 Insights
CB2 Insights has a mission to mainstream medical cannabis into
traditional healthcare. We are a research and technology company,
offering a suite of data and technology solutions as a full service
clinical CRO, specializing in Phase II, III and IV, post-marketing,
observational and experimental trials in a range of therapeutic
areas for sponsors worldwide. CB2 Insights helps industry
stakeholders create a strong value story with Real World Evidence,
generation of safety and efficacy data, operating in two segments:
clinical solutions and data solutions.
For more information please visit www.cb2insights.com.
About MyAccess Clinics
MyAccess Clinics provide expert care for patients with unmet
needs, which licensed medicines have failed to address, through the
use of ‘specials’ medicines. ‘Specials’ are unlicensed medicines
that are specifically manufactured or obtained in order to meet a
patient's individual clinical need. An example of this would be
unlicensed cannabis-based products for medicinal use, which our
private clinics specialize in.
MyAccess Clinics is a wholly-owned subsidiary of leading global
medical cannabis company, Althea Group Holdings Ltd (ASX:AGH).
For more information please visit
https://myaccessclinics.co.uk/
For additional information, please contact:
Dan Thompson – CB2 Insights1.855.847.4999
ext 120dan.thompson@cb2inights.com
Julia Maguire – Althea Group / The Capital
Network+61 419 815 386julia@thecaptialnetwork.com.au
Forward Looking Statements
Statements in this news release that are forward-looking
statements are subject to various risks and uncertainties
concerning the specific factors disclosed here and elsewhere in
CB2’s filings with Canadian securities regulators. When used in
this news release, words such as "will, could, plan, estimate,
expect, intend, may, potential, believe, should," and similar
expressions, are forward-looking statements.
Forward-looking statements may include, without limitation,
statements regarding the opportunity to provide services and
software to the U.S. cannabis industry.
Although CB2 has attempted to identify important factors that
could cause actual results, performance or achievements to differ
materially from those contained in the forward-looking statements,
there can be other factors that cause results, performance or
achievements not to be as anticipated, estimated or intended,
including, but not limited to: dependence on obtaining regulatory
approvals; investing in target companies or projects which have
limited or no operating history and are subject to inconsistent
legislation and regulation; change in laws; reliance on management;
requirements for additional financing; competition; hindering
market growth and state adoption due to inconsistent public opinion
and perception of the medical-use and recreational-use marijuana
industry and; regulatory or political change.
There can be no assurance that such information will prove to be
accurate or that management's expectations or estimates of future
developments, circumstances or results will materialize. As a
result of these risks and uncertainties, the results or events
predicted in these forward-looking statements may differ materially
from actual results or events.
Accordingly, readers should not place undue reliance on
forward-looking statements. The forward-looking statements in this
news release are made as of the date of this release. CB2 disclaims
any intention or obligation to update or revise such information,
except as required by applicable law, and CB2 does not assume any
liability for disclosure relating to any other company mentioned
herein.
No securities regulator or exchange has reviewed,
approved, disapproved, or accepts responsibility for the content of
this news release.
CB2 Insights (CSE:CBII)
Historical Stock Chart
From Jun 2024 to Jul 2024
CB2 Insights (CSE:CBII)
Historical Stock Chart
From Jul 2023 to Jul 2024